Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular predictors of response to pembrolizumab in thymic carcinoma.

Cell reports. Medicine - 21 Sept 2021

He Yongfeng, Ramesh Archana, Gusev Yuriy, Bhuvaneshwar Krithika, Giaccone Giuseppe

Abstract excerpt

Thymic carcinoma is rare and has a poorer prognosis than thymomas. The treatment options are limited after failure of platinum-based chemotherapy. We previously performed a single-center phase II study of pembrolizumab in patients with advanced thymic carcinoma, showing a 22.5% response rate. Here, we characterize the genomic and transcriptomic profile of thymic carcinoma samples from 10 patients (5...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Tumor Burden
Share to Antibodies, Monoclonal, Humanized
Share to Gene Expression Profiling

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Signal Transduction

Share to Thymoma

Share to Thymus Neoplasms

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 34622229
DOI: 10.1016/j.xcrm.2021.100392
PMCID: PMC8484507

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular predictors of response to pembrolizumab in thymic carcinoma.PMID 34622229Read ↗

Clinicopathologic Significance and Immunogenomic Analysis of Programmed Death-Ligand 1 (PD-L1) and Programmed Death 1 (PD-1) Expression in Thymic Epithelial TumorsSemantic proximity Read ↗

Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors.Semantic proximity Read ↗

Point of view: Genomic landscape and molecularly informed therapy in thymic carcinoma and other advanced thymic epithelial tumors.Semantic proximity Read ↗

Comprehensive Genomic Profiling of 274 Thymic Epithelial Tumors Unveils Oncogenic Pathways and Predictive Biomarkers.Semantic proximity Read ↗

Medical treatment involving investigational drugs and genetic profile of thymic carcinoma.Semantic proximity Read ↗

Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors.Semantic proximity Read ↗

Characteristics of Genomic Mutations and Signaling Pathway Alterations in Thymic Epithelial TumorsSemantic proximity Read ↗

Mutations of epigenetic regulatory genes are common in thymic carcinomas.Semantic proximity Read ↗

The Molecular Landscape of Thymic Epithelial Tumors: A Comprehensive ReviewSemantic proximity Read ↗

Genetic insights into thymic carcinomas and thymic neuroendocrine neoplasms denote prognosis signatures and pathways.Semantic proximity Read ↗

Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.Semantic proximity Read ↗

Genomic characterization of thymic epithelial tumors in a real-world datasetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.